• Molecular NameClopenthixol
  • SynonymZuclopenthixol; zuclopenthixol acetate; zuclopenthixol decanoate; zuclopenthixol dihydrochloride; Zuclopenthixolum [latin]; Zuclopentixol [spanish]
  • Weight400.974
  • Drugbank_IDN/A
  • ACS_NO982-24-1
  • Show 2D model
  • LogP (experiment)4.18
  • LogP (predicted, AB/LogP v2.0)4.3
  • pkaN/A
  • LogD (pH=7, predicted)3.51
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.53
  • LogSw (predicted, AB/LogsW2.0)0.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.05
  • No.of HBond Donors1
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds5
  • TPSA52.01
  • StatusN/A
  • AdministrationN/A
  • PharmacologyA typical antipsychotic of the thioxanthene class. It mainly acts by antagonism of D1 and D2 dopamine receptors. Zuclopenthixol also has high affinity for alpha1-adrenergic and 5-HT2 receptors. It has weaker histamine H1 receptor blocking activity, and even lower affinity for muscarinic cholinergic and alpha2-adrenergic receptors.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding98.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmThe metabolism of zuclopenthixol is mainly by sulphoxidation, side chain N-dealkylation and glucuronic acid conjugation. The metabolites are devoid of pharmacological activity.
  • Half life20 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityAlthough there have not been any cases of overdosage reported, the symptoms are likely to be somnolence, coma, extrapyramidal symptoms, convulsions, hypotension, shock, or hyper- or hypothermia.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A